<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45325">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02034526</url>
  </required_header>
  <id_info>
    <org_study_id>M-2013-225-13</org_study_id>
    <nct_id>NCT02034526</nct_id>
  </id_info>
  <brief_title>Reducing Atrial Pacing Rate to Reduce Atrial Fibrillation in Patients With Sick Sinus Syndrome.</brief_title>
  <acronym>DANPACEII</acronym>
  <official_title>A Randomised Controlled Trial of Reducing Atrial Pacing Rate to Reduce Atrial Fibrillation in Patients With Sick Sinus Syndrome and Dual Chamber Pacemaker.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <authority>Denmark: National Board of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is prevalent in patients with sick sinus syndrome (SSS) and
      associated with an increased risk of stroke and death. Within the first two years after
      pacemaker implantation almost half of the patients are diagnosed with AF. Studies have
      indicated that an increased amount of stimulation from the pacemaker in the atria is
      associated with an increased amount of AF.

      The aim of the present study is to test the hypothesis that a reduction of stimulation from
      the pacemaker in the atria, and reducing the minimal heart rate, increases the time to AF.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to first episode of AF&gt;6 min detected by the pacemaker</measure>
    <time_frame>Within two years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first episode of AF&gt;6 hours detected by the pacemaker</measure>
    <time_frame>Within two years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first episode of AF&gt;24 hours detected by the pacemaker</measure>
    <time_frame>Within two years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to DC cardioversion or medical cardioversion for AF</measure>
    <time_frame>Within two years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to stroke, TCI, or thromboembolic event</measure>
    <time_frame>Within two years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>Within two years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>After 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life assessment with SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6MHWT</measure>
    <time_frame>After 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>6-minute hall walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to need for reprogramming of the pacing rate (cross-over)</measure>
    <time_frame>Within 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Sinus Node Disease</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>DDDR-60</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DDD-40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DDD, lower pacing rate 40 bpm, RR function off</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DDDR-60</intervention_name>
    <description>DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)</description>
    <arm_group_label>DDDR-60</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DDD-40</intervention_name>
    <description>DDD, lower pacing rate 40 bpm, RR function off</description>
    <arm_group_label>DDD-40</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sick sinus syndrome and indication for first-time implantation of a DDD pacemaker:
             symptomatic sinus pauses (&gt;2 sec) or bradycardia with or without paroxysmal AF.

          -  Age â‰¥18 years.

          -  Patient informed consent.

        Exclusion Criteria:

          -  Permanent or persisting (&gt;7 days) AF prior to implantation.

          -  Persisting symptomatic sinus bradycardia and/or chronotropic incompetence where
             DDD-pacing at a frequency of &gt;40 bpm is indicated (verified with long term ECG
             monitoring).

          -  Persisting second or third degree AV block.

          -  Life expectancy &lt;2 years.

          -  Participation in another interventional research study.

          -  Indication for implantable cardioverter defibrillator (ICD) or cardiac
             resynchronization therapy (CRT).

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens C Nielsen, prof., DMSc,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens C Nielsen, prof., DMSc.</last_name>
    <phone>+ 45 78 45 00 00</phone>
    <email>jenniels@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mads B Kronborg, MD, PhD</last_name>
    <phone>+ 45 78 45 00 00</phone>
    <email>mads.brix.kronborg@ki.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens C Nielsen, prof., DMSc.</last_name>
      <phone>+45 78 45 00 00</phone>
      <email>jenniels@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Mads B Kronborg, MD, PhD.</last_name>
      <phone>+45 78 45 00 00</phone>
      <email>mads.brix.kronborg@ki.au.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Jens C Nielsen, prof., DMSc,</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>January 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Jens Cosedis Nielsen</investigator_full_name>
    <investigator_title>Jens Cosedis Nielsen, professor, MD, DMSc, PhD</investigator_title>
  </responsible_party>
  <keyword>Sinus node disease</keyword>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Pacing</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Sick Sinus Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
